Since the discovery of the 2,4 (1H,3H)-pyrimidinediones as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase (RT) this class of compounds has yielded a number of N-1 acyclic substituted pyrimidinediones with substantial antiviral activity, which is highly dependent upon their molecular fit into the binding pocket common to this inhibitory class. We have specifically examined the structure activity relationships of compounds with chemical modification made by substituting homocyclic rather than acyclic moieties at N-1 of the pyrimidinedione. Seventy-four compounds were synthesized and evaluated for antiviral activity against HIV-1 and HIV-2. The homocyclic modifications resulted in compounds with significant activity against both HIV-1 and HIV-2, suggesting these compounds represent a new class of non-nucleoside RT inhibitors. The structure-activity relationship (SAR) evaluations indicated that cyclopropyl, phenyl and 1-or 3-cyclopenten-1-yl substitutions at the N-1 of the pyrimidinedione, the addition of a methyl linker between the cyclic moiety and the N-1 and the addition of a benzoyl group at the C-6 of the pyrimidinedione had the greatest contribution to antiviral activity. Five pyrimidinedione analogues with therapeutic indexes (TIs)> >450,000 and a specific analogue (1-cyclopropylmethyl-5isopropyl-6-(3,5-dimethylbenzoyl)-2,4(1H,3H)pyrimidinedione), which exhibited a TI of > >2,000,000, were identified. None of the analogues were cytotoxic to target cells at the highest in vitro test concentration, which is the upper limit of compound solubility of the analogues in aqueous solution. Thus, we have identified a series of pyrimidinediones with substantially improved antiviral efficacy and range of action and with significantly reduced cellular cytotoxicity.
The application of multidrug cocktails to combat the progression of HIV disease using inhibitors of reverse transcriptase (RT), protease and fusion has allowed the medical community to make significant progress in treatment practices, and has offered the potential of ultimately controlling the AIDS pandemic. Highly active antiretroviral therapies (HAART) are now the standard of care for AIDS patients. Unfortunately, progress towards effective chemotherapeutic control of HIV infection has been negatively affected by issues of patient compliance, drug toxicity, expense and the development of drug resistance. Thus, although progress has been made, there is still the urgent need to develop new antiviral agents with novel mechanisms of action, reduced toxicity or reduced rates of selection of resistant virus strains, or to further optimize the antiviral activity of known drugs. The currently approved drugs for treatment of HIV-1 infections can be divided into four classes: RT inhibitors, protease inhibitors, entry inhibitors and fusion inhibitors. The RT inhibitors can be further subdivided into nucleoside RT inhibitors (NRTIs) such as zidovudine (AZT), zalcitabine, didanosine, stavudine and lamuvidine and nonnucleoside RT inhibitors (NNRTIs) such as nevirapine, delaviridine and efavirenz. The NNRTIs are potent and selective inhibitors of HIV-1 replication, which are characterized by binding to a deep hydrophobic pocket near the polymerase active site in the p66 palm subdomain of the enzyme (Condra et al., 1992; Kohlstaedt et al., 1992; Smerdon et al., 1994) , having relatively no activity against HIV-2 (De Clercq, 1993; , and resulting in the rapid generation of drug-resistant HIV mutants (De Clercq, 1994) .
The first demonstration of antiviral activity associated with the 2,4(1H, 3H)-pyrimidinediones was the discovery of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT, [1]; Figure 1) Miyasaka et al., 1989) . HEPT, a 6-substituted acyclouridine derivative, is a novel, potent and specific non-nucleoside inhibitor of HIV-1 reverse transcriptase. A number of HEPT analogues have been synthesized, such as 6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-ethyluracil [2] (Baba et al., 1992) which inhibits HIV-1 replication at nanomolar concentrations. 6-Benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC 422, [3] ) (Baba et al., 1994; De Clercq, 1999) has been tested clinically but was subsequently withdrawn due to insufficient reduction in plasma viral load in Phase III studies. Other HEPT analogues have also been described, including 6-[(3,5dimethylbenzyl)-5-ethyl-1-(ethylthio)methyl]uracil [4] (Danel et al., 1996), 6-[(3,5-dimethylphenyl) selenyl]-1-(ethoxymethyl)-5-isopropyluracil [5] (Kim et al., 1996) , 3,4dihydro-2-sec-butoxy-6-(3,5-dimethylbenzyl)-4-oxo-pyrimi dine [6] (Mai et al., 1999) , 5-ethyl-6-methyl-3-carbetoxy-4-[(3′,5′-dimethylphenyl)thio]-pyridine-2(1H)-one [7] (Dolle et al., 1995) . We have previously reported the biological anti-HIV-1 activity and resistance profile of another highly potent HEPT analogue, 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine and the initial identification of the first member of the pyrimidinedione series of compounds described herein (1-(3-cyclopenten-1-ylmethyl)-5-ethyl-6-(3,5-dimethylbenzoyl)-2,4(1H,3H)pyrimidinedione; (Buckheit et al., 2001) .
We undertook to specifically examine the antiviral structure-activity relationship (SAR) of substituting a homocyclic moiety at N-1 of the pyrimidinedione. A number of cyclic substitutions were analysed including cyclopropyl, cyclobutyl, cyclopentyl, phenyl and 1-, 2-or 3-cyclopenten-1-yl. These efforts have identified a series of potent 2,4(1H,3H)-pyrimidinedione analogues with sub-nanomolar antiviral activities and no apparent cytotoxicity up to their limit of solubility in aqueous solutions. RW Buckheit Jr et al. 260 ©2007 International Medical Press General procedure for the synthesis of tosylates in Figure 4 . 
Antiviral assays
Antiviral activity of the compounds was measured by inhibition of virus-induced cytopathic effects (CPE) using MT-4 cells infected with HIV-1 IIIB (Pauwels et al., 1988) or CEM-SS cells infected with HIV-1 RF or HIV-2 ROD . Briefly, both methods rely on virus-induced CPE induction with cell survival (cytoprotection) measured using a mitochondria-activated dye to assess cell viability by a colourimetric endpoint. AZT was used as a positive-control compound in all studies performed and exhibited the expected level of activity ranging between 1 and 10 nM. The absorbance of 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) at 540 nm is used to determine cell survival at day 4 following infection of MT-4 cells. For the CEM-SS assay 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium hydroxide (XTT) dye reduction following activation with phenazine methosulfate at 450/650 nM is used to measure cell survival 6 days after infection. For both assays the EC 50 (concentration resulting in 50% reduction in virus replication) and TC 50 (concentration resulting 50% loss of cell viability in cells without virus) values are calculated by linear regression analysis. A therapeutic index (TI) is calculated by dividing the TC 50 by the EC 50 . For the purposes of this study, moderately and significantly improved antiviral efficacy were defined as 200,000<TI<450,000 and TI>450,000, respectively.
Results

Activities of homocyclic-modified HEPT against HIV-1
Historically, a large number of HEPT analogues have been synthesized and with acyclic moieties at the N-1 of the pyrimidinedione (R, Figure 7 ) and these analogues demonstrated a strong SAR for substitutions in the HEPT molecule. These previously reported studies suggested that position 6 on the pyrimidinedione and positions 3 and 5 of the benzoyl, phenoxy or phenylthio group were of particular importance for realization of antiviral activity among these compounds. Thus, in our studies we have limited the The antiviral efficacy and toxicity results were obtained from a single representative antiviral assay with appropriate control compounds selected from a minimum of two replicate antiviral assays. We have demonstrated that the standard error between multiple antiviral assays averaged less than 10% of the respective mean 50% effective concentration (EC 50 ) or TC 50 (concentration of 50% loss of cell viability in cells without virus) values. *See product of Figure 5 . † Compounds with therapeutic indices (TIs)>450,000 are defined as highly active inhibitors. ‡ A, cyclopropyl; B, cyclobutyl; C, cyclohexyl; D, phenyl; E, 1-cyclopenten-1-yl; F, 3-cyclopenten-1-yl. NA, not applicable; ND, not determined. Table 1 . Antiviral activity and toxicity of pyrimidinediones possessing a methyl linker modifications to the general HEPT structure at R 1 , R 2 , R 3 and X (Figure 7) to those which have been previously associated with favourable geometry or antiviral activity, as reported in the literature. The HEPT series of compounds has been associated with strong antiviral activity. Thus, to differentiate the currently synthesized pyrimidinedione analogues from previously reported HEPT derivatives, we developed the following criteria for grading antiviral activity. Compounds with TIs <200,000 were considered to be of no improvement on antiviral activity over current HEPT analogues and were thus not considered suitable for further investigation. Compounds with TIs between 200,000 and 450,000 were graded as moderately active. The moderately active designation was defined independently of any observed compound cytotoxicity. Highly active compounds with a significant rationale for continued therapeutic development were defined as those compounds with TIs >450,000 and with no detectable toxicity up to the limit of compound solubility in aqueous solution. Using these criteria, compounds [19], [38], [49] and [63] were graded as highly active in CEM-SS cells and compound [30] was identified as highly active in compound [62] was highly active in both cell-based assay systems. In general, minor discordance between the antiviral results in MT-4 and CEM-SS cells was observed. These differences most probably relate to the fact that the MT-4 cells are constitutively infected and express low levels of HTLV-1 (Harada et al., 1985) and in the presence of the HTLV-1 transactivator protein in MT-4 cells, HIV-1 replicates faster and with greater CPE induction in MT-4 cells than in CEM-SS cells. Thus, in MT-4 cells, HIV-1 infection results in a higher relative multiplicity of infection (MOI) and we have noted variability in the sensitivity of the various pyrimidinediones to viral MOI in cell-based infections. Thus, the lack of complete correspondence between activity in HIV-1 IIIB -infected MT-4 The antiviral efficacy and toxicity results were obtained from a single representative antiviral assay with appropriate control compounds selected from a minimum of two replicate antiviral assays. We have demonstrated that the standard error between multiple antiviral assays averaged less than 10% of the respective mean 50% effective concentration (EC 50 ) or TC 50 (concentration of 50% loss of cell viability in cells without virus) values. *See product of Figure 6 . † Compounds with therapeutic indices (TIs)>450,000 are defined as active against HIV-1. ‡ A, cyclopentyl; B, 1-cyclopenten-1-yl; C, 2-cyclopenten-1-yl; D, 3-cyclopenten-1-yl. ND, not determined. As previously noted, the deep hydrophobic pocket in the p66 palm domain of RT is highly structured and thus requires that potential inhibitors be able to enter the pocket and interfere with polymerase activity by allosteric means. Specific analysis of the active derivatives in Table 1 shows that the cyclic moieties are limited to cyclopropyl, phenyl and 1-and 3-cyclopenten-1-yl pyrimidinedione derivatives. The pyrimidinedione derivatives with cyclobutyl, cyclopentyl or cyclohexyl at the N-1 position had reduced antiviral activity, and, by the definitions for identification of active compounds used here, were not considered development candidates. Some of these derivatives did achieve nanomolar and sub-nanomolar EC 50 concentrations (cyclobutyl: The restriction on the form and distance of the cyclic moiety from the N-1 position is further illustrated in Table 2 . The derivatives displayed in Table 1 have a methyl linker between the cyclic substitution and the N-1 of the pyrimidinedione. In Table 2 an ethyl linker was incorporated between N-1 and the added cyclic group . Compound [30] (1-cyclopentylmethyl-5-ethyl-6-(3,5-dimethylbenzoyl)-2,4(1H,3H)-pyrimidinedione) was previously identified as active in the MT-4 assay, but when the distance between N-1 and the cyclic substitution was increased all activity was lost ([68], 1-[2-(cyclopentyl)ethyl]-5-ethyl-6-(3,5-dimethylbenzoyl)-2,4 (1H,3H)-pyrimidinedione). Similar results were seen for compounds [52], [62] and [63] following incorporation of an ethyl spacer between the cyclic substituent and the N-1 position. Interestingly, compound [78] with a 2-cyclopenten-1-yl ethyl side substituent was active with a TI of 569,608 (EC 50 0.19 nM and TC 50 1,100 μM).
Although the corresponding N-1 methyl-substituted 2-cyclopenten-1-yl was not synthesized (Table 1) , the 1-cyclopenten-1-yl [72] or 3-cyclopenten-1-yl [84] were 221-and 121-fold, respectively, less active than [78] without increased cytotoxicity. Thus, increasing the spacer length between the N-1 position of the pyrimidinedione and the cyclic moiety resulted in loss of antiviral activity; however, antiviral activity may be regained by further alterations in the positioning and composition of the cyclic substitution.
The most active inhibitors in rank order based on EC 50 concentrations in CEM-SS cells infected with HIV-1 RF are presented in Table 3 . The activity of these compounds against HIV-1 ranges from 0.1 nM for compound [49] to 2.6 nM for compound [81] and includes 15 compounds. Of these 15 active congeners, five also appeared among the most active inhibitors of HIV-2 (Table 4 ). The ten most active compounds presented in Table 3 have the methyl linker, except compounds [78], [83] and [81] with the ethyl linker. As can be seen from the data presented in Table 3 , cyclopropyl, cyclobutyl, phenyl, and 1-, 2-and 3-cyclopenten-1-yl moieties are all represented, as well as phenylthio, phenoxy and benzoyl groups at position 6 of the pyrimidinedione. However, most of the compounds with the greatest TI values (compounds [49], [19], [62] and [63] ), have a benzoyl group, with the exception of compound [38], which possesses a phenylthio, and compound [78], which has the ethyl linker and a phenoxy group.
Activities of homocyclic-modified HEPT against HIV-2
The activity of the compounds against HIV-2 followed a similar pattern compared with the anti-HIV-1 activity of the molecules in the SAR series. It was again apparent that the compounds with the ethyl rather than methyl linker between the cyclic substitution and the N-1 of the pyrimidinedione were less active (Table 2) . Within the methyl linker series (Table 1) , compound [19] possessed the greatest activity against HIV-2 ROD with an EC 50 concentration of ~100 nM and a TI>13,030 in CEM-SS cells. In the methyl linker series, the most potent inhibitors possess activity between 0.1 and 1.0 μM. Compounds found to be active against HIV-2 were found to possess cyclopropyl, phenyl or 1-cyclopenten-1-yl at the N-1 position. The nine most active compounds based on direct comparison of EC 50 values obtained from CEM-SS cells infected with HIV-2 ROD are presented in 
Toxicity to target cells
The results reported in Table 1 and Table 2 suggest that a complex pattern of chemical modifications give rise to compounds with greater or lesser levels of cellular toxicity. However, in general, the presence of the phenylthio group at position C-6 of the pyrimidinedione results in molecules with increased level of toxicity. Many compounds with the phenoxy group at C-6 are also quite toxic. Compounds with a carbonyl group at the C-6 site generally seem to have less toxic effects on the target cells. Within the series of molecules, however, the nature of the homocyclic substitution and changes at R 1 , R 2 and R 3 have variable and complex effects on both efficacy and toxicity.
Discussion
We have synthesized a rational set of 2,4(1H,3H)-pyrimidinediones by substituting cyclic moieties at N-1 of the pyrimidinedione. An analogue set of 74 compounds yielded select compounds with high antiviral potency, low toxicity and therapeutic indexes in HIV-1 RF -infected CEM-SS cells ranging from 450,000 to 2,000,000. SAR evaluations demonstrated that cyclopropyl, phenyl and 1-or 3-cyclopenten-1-yl substitutions at the N-1 of the pyrimidinedione yields molecules with the most significant improvements in activity, especially when coupled with a methyl linker between the cyclic group and the N-1 site. Substitutions at the C-6 site of the pyrimidinedione also contributed to both compound efficacy (benzoyl substitution) and/or compound toxicity (phenylthio and phenoxy substitutions). This SAR series and the lead compounds that are defined represent a significant improvement on the activity of previously reported HEPT analogues and other 2,4(1H,3H)-pyrimidinedione analogues and have been identified as a potentially useful new chemotype variation for the development of new and more potent NNRTIs. In addition, the cyclic modifications at the N-1 of the pyrimidinedione have increased the range of action of the HEPT to include significant levels of activity against HIV-2. Although activity against HIV-2 has been reported for some NNRTIs, the TI of these compounds reported here is much greater when tested against HIV-2 than that reported for any other NNRTI. We are currently investigating the active compounds more closely, determining resistance patterns, pharmacokinetic parameters, and elucidating a novel mechanism of action involving virus entry (Buckheit et al., 2001) .
